An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin
Status:
Completed
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
This is a single center, prospective, randomized, placebo -controlled, parallel design and
double blind study to evaluate oxidative stress, inflammation and hypertension markers and
mediators before and after treatment with dapagliflozin.